Objectives: To ensure the accuracy of susceptibility testing methods for ceftazidime/avibactam.
Introduction
The adoption of ceftazidime/avibactam for the treatment of carbapenem-resistant Gram-negative infections has been swift and is supported by clinical reports demonstrating efficacy superior to that of traditional treatment regimens.
1,2 However, the availability of accurate susceptibility testing methods against these target pathogens has lagged behind this rapid adoption. Given the difficulties and delays in implementing FDA-cleared automated commercial antimicrobial susceptibility (cAST) devices, laboratories often turn to manual methods such as gradient strips and discs to provide susceptibility information. Consequently, there is an urgent need to evaluate the accuracy of available susceptibility testing methods for ceftazidime/avibactam against the target pathogens for which they are used in clinical practice.
Materials and methods

Bacterial isolates
One hundred and two Gram-negative isolates were included: 69 ceftazidime-and meropenem-resistant Klebsiella pneumoniae and 33 MDR non-K. pneumoniae Gram-negative isolates (Table 1) . These were clinical isolates from our in-house biorepository and the FDA-CDC Antimicrobial Resistance Bank. 3 K. pneumoniae ATCC 700603 was used for quality control on each day of testing. Isolates were maintained at #80 C in CAMHB with 20% glycerol and subcultured twice prior to use on tryptic soy agar with 5% sheep's blood.
Susceptibility testing
Ceftazidime and avibactam powder were purchased commercially (SigmaAldrich, St Louis, MO, USA). Broth microdilution (BMD) testing was performed 
Agreement analysis
Using BMD as the reference method, essential agreement (EA), categorical agreement (CA), major errors (MEs) and very major errors (VMEs) were assessed according to standard definitions. 8 The primary outcome was equivalency as defined by the CLSI threshold of ME and VME rates of ,3%. 9, 10 The acceptance criterion of .89.9% for EA and CA was also evaluated. 8 Additionally, given that the bacterial population evaluated in this study was not binomial (21.6% of the 102 isolates were within 1 log 2 dilution of the susceptible/resistant MIC breakpoint), the error-rate bound method was also calculated. 8 Additionally, data from the 102 isolates in this study were combined with data from 74 carbapenem-resistant Enterobacteriaceae isolates from Shields et al. 11 and 356 Gram-negative isolates from the ceftazidime/avibactam new drug application (320 Enterobacteriaceae, 36 non-fermenting isolates). 12 Optimal thresholds were analysed using the error-rate bound and model-based approaches of the diffusion breakpoint estimation testing software package 13 according to CLSI M23-A4 guidelines. 9 
Results
By BMD, 80 (78.4%) of 102 isolates were susceptible to ceftazidime/avibactam whereas 65 (94.2%) of the ceftazidime-and meropenem-resistant K. pneumoniae isolates were susceptible, with MIC 50 /MIC 90 of 1/4 mg/L. Only 15 (45.5%) of the MDR non-K. pneumoniae isolates were susceptible, with MIC 50 /MIC 90 of 32/256 mg/L by BMD. Table 1 displays the performance of the three test methods compared with BMD. None of the three methods met either equivalency threshold. Using the error-rate bound method, all three methods met acceptance criteria for the highest BMD MIC thresholds (16 or 32 mg/L) as there were no VMEs observed. None of the three methods met the acceptance criteria for either of the two lower MIC thresholds.
Against only the ceftazidime-and meropenem-resistant K. pneumoniae isolates, Etest met the equivalency threshold as there were no MEs or VMEs observed. The 30/20 lg disc again did Wenzler et al.
not meet either threshold, although the percentage CA and ME rates were slightly better. The 10/4 lg discs performed better against the ceftazidime-and meropenem-resistant K. pneumoniae isolates and did meet both equivalency thresholds. There were no VMEs observed by any method. Versus the collection of MDR non-K. pneumoniae, none of the three methods met either equivalency threshold. The Etest had the highest CA and the lowest rate of MEs. The 30/20 lg discs outperformed the 10/4 lg discs. There were no VMEs observed by any method. For the 476 Enterobacteriaceae from the three studies included in the pooled analysis, an optimal susceptible/resistant disc diffusion breakpoint of 19 mm was identified by the error-rate bound and non-parametric spline model approach of the optimal threshold analysis. A breakpoint of 18 mm was identified by the logistic model, although the 19 and 18 mm breakpoints had identical probability of producing a correct MIC and disc zone of diffusion over any range of true MIC values and sets of breakpoints (97%). The current CLSI disc diffusion breakpoint of 20 mm was selected by the error-rate bound method only 25.8% of the time among 5000 bootstrapped samples, was not identified by either the logistic or the spline model and had slightly lower probability of producing correct results (95% versus 97%). For the 56 non-fermenting Gram-negative isolates from our study and the ceftazidime/avibactam new drug application, an optimal susceptible/resistant disc diffusion breakpoint of 20 mm was identified by all three methods, with an 88% probability of correct classification.
Discussion
In this study, the FDA-cleared 30/20 lg discs did not meet the primary or secondary thresholds for equivalency against either group of organisms tested. The 10/4 lg discs performed better than the Wenzler et al.
30/20 lg discs against the ceftazidime-and meropenem-resistant K. pneumoniae isolates and did meet both equivalency thresholds. The 30/20 lg discs performed slightly better than the 10/4 lg discs against the MDR non-K. pneumoniae isolates, although both methods had high rates of MEs and did not meet equivalency standards. Etest consistently had the highest performance and was the most reliable method against all the isolates tested in this analysis.
Given that carbapenem-resistant organisms are the target pathogens for which ceftazidime/avibactam is used in clinical practice, the Etest may be preferred over discs by clinical microbiology laboratories until automated cAST devices are available. By combining our data with multiple other sources, we were able to evaluate optimal 30/20 lg disc diffusion breakpoints for ceftazidime/avibactam against Enterobacteriaceae and nonfermenting Gram-negative isolates. The diffusion Breakpoint Estimation Testing Software model-based approaches used in this study are more precise than traditional error-rate bound methods as they use probability to account for the inherent variability of the tested susceptibility methods. Pooled analysis of 476 Enterobacteriaceae isolates defined 19 mm as the optimal susceptibility breakpoint for the 30/20 lg discs, although this threshold demonstrated a similar classification probability compared with the current CLSI breakpoint of 20 mm (97% versus 95%). Analysis of 56 non-fermenting Gram-negative isolates identified 20 mm as the optimal breakpoint. These results support a single 30/20 lg disc diffusion susceptible/resistant breakpoint of 20 mm, as is currently recommended by CLSI.
In this study the probability of error increased for pathogens with an MIC .2 mg/L, and the highest probability of testing errors occurred for isolates with an MIC near the susceptible breakpoint (8 mg/L). Additionally, disc diameter zones of inhibition that grouped around the susceptible breakpoint led to the majority of error classifications. This was particularly true for the 30/20 lg discs (Figure 2a) as opposed to the 10/4 lg discs (Figure 2b) . This difference could be due to the different disc potencies and could potentially be resolved by the addition of an intermediate MIC and disc diffusion zone categorization. CLSI is currently considering adding a note regarding uncertainty around disc zones in the range where MEs were observed.
Limitations of this study include the number of isolates tested. Additionally, only one manufacturer and lot of CAMHB and Mueller-Hinton agar were used for this study. Finally, molecular analyses were not performed for all isolates, which precluded assessment of underlying genetic mechanisms of resistance and clonality.
Conclusions
Our data indicate that the Etest is a suitable alternative to BMD for testing ceftazidime/avibactam against ceftazidime-and meropenem-resistant K. pneumoniae, whereas the FDAcleared 30/20 lg discs are not. The rate of false resistance remains concerning and clinicians should interpret MICs near the breakpoint with caution and consider repeat testing (or validation at a reference laboratory) to avoid unnecessary use of agents that are more toxic and less effective. Clinical microbiology laboratory directors should perform adequate in-house verifications before adopting any of these AST methods for ceftazidime/avibactam.
